Thera-SAbDab

ZIMBERELIMAB

>   Structural Summary
TherapeuticZimberelimab
TargetPDCD1
Heavy ChainQLQLQESGPGLVKPSETLTLTCTVSADSISSTTYYWVWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTVSVDTSKNQFSLKLNSVAATDTALYYCARHLGYNGRYLPFDYWGQGTLVTVSS
Light ChainQSALTQPASVSGSPGQSITISCTGTSSDVGFYNYVSWYQQHPGKAPELMIYDVSNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSISTWVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2020
INN Year RecommendedNone
Companies InvolvedHarbin Gloria Pharmaceuticals, WuXi Biologics, Arcus Biosciences, Beijing Cancer Hospital, Guangzhou Gloria Biosciences, Strata Oncology
Conditions Approvedna
Conditions ActiveCervical cancer, Non-small cell lung cancer, Breast cancer, Cancer, Ovarian cancer, Pancreatic cancer, Solid tumours, Hodgkin's disease
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]